NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

COYA

Coya Therapeutics Inc

Apr 29 • 04:00PM ET

6.10

Dollar change -0.07
Percentage change -1.13	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY ARWR IONS MDGL ARVN AKRO MRNA VRTX NBIX BMRN

| Held by: VTI VXF IWC DFAC DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.98	Insider Own	7.04%	Shs Outstand	16.71M	Perf Week	-8.13%
Market Cap	102.05M	Forward P/E	-	EPS next Y	-1.51	Insider Trans	1.25%	Shs Float	15.55M	Perf Month	-7.01%
Income	-14.88M	PEG	-	EPS next Q	-0.19	Inst Own	26.58%	Short Float	2.16%	Perf Quarter	4.99%
Sales	3.55M	P/S	28.75	EPS this Y	-3.07%	Inst Trans	237.95%	Short Ratio	3.31	Perf Half Y	-38.45%
Book/sh	2.37	P/B	2.58	EPS next Y	-49.99%	ROA	-34.76%	Short Interest	0.34M	Perf Year	-27.64%
Cash/sh	2.29	P/C	2.66	EPS next 5Y	5.01%	ROE	-39.56%	52W Range	4.65 - 10.24	Perf YTD	6.46%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-89.45%	ROI	-37.60%	52W High	-40.43%	Beta	0.54
Dividend TTM	-	Quick Ratio	11.59	Sales past 5Y	-10.20%	Gross Margin	99.23%	52W Low	31.18%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	11.59	EPS Y/Y TTM	-16.57%	Oper. Margin	-484.65%	RSI (14)	51.29	Volatility	7.90% 10.47%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-40.79%	Profit Margin	-418.70%	Recom	1.00	Target Price	15.62
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-298.52%	Payout	-	Rel Volume	0.30	Prev Close	6.17
Sales Surprise	100.00%	EPS Surprise	34.64%	Sales Q/Q	-99.97%	Earnings	Mar 18 BMO	Avg Volume	101.43K	Price	6.10
SMA20	5.68%	SMA50	-2.22%	SMA200	-4.91%	Trades		Volume	30,373	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-24	Initiated	D. Boral Capital	Buy	$15

Apr-29-25 09:40AM	Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-25-25 11:27AM	Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release (Seeking Alpha) -5.36%
Apr-24-25 08:00AM	Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia (ACCESSWIRE)
Apr-23-25 09:55AM	Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? (Zacks)
Apr-21-25 09:51AM	Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) (Business Wire) +8.56%
07:00AM	Loading…
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-11-25 03:02PM	Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-01-25 08:15AM	Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 (Business Wire)
Mar-27-25 12:00PM	What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock (Zacks) +5.84%
09:55AM	Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet (Zacks)
09:40AM	Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? (Zacks)
Mar-26-25 08:15AM	Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program (Business Wire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-18-25 08:15AM	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results (Business Wire) -5.84%
Feb-25-25 08:15AM	Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations (Business Wire)
01:30PM	Loading…
Feb-06-25 01:30PM	Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing (Benzinga) +7.20%
08:00AM	Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimers Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development (Business Wire)
Feb-04-25 08:15AM	Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-27-25 02:54AM	An ALS treatment wave is approaching, and this biotech CEO is ready to surf (Pharma Voice)
Jan-21-25 08:15AM	Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases (Business Wire) +5.20%
08:00AM	EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases (Benzinga)
Dec-18-24 08:15AM	Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) (Business Wire) -7.13%
Nov-25-24 08:15AM	Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-19-24 08:15AM	Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders (Business Wire)
Nov-06-24 08:00AM	Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results (Business Wire) +7.72%
Nov-01-24 08:15AM	Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer (Business Wire)
Oct-30-24 08:29AM	Coya Therapeutics Reports Positive Phase 2 Alzheimers Trial Results (TipRanks) -9.70%
Oct-29-24 02:36PM	Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study (Benzinga) -27.67%
06:30AM	Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) (Business Wire)
Oct-28-24 08:00AM	Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimers Disease (Business Wire) +13.73%
04:05PM	Loading…
Oct-23-24 04:05PM	Coya Therapeutics Announces Closing of $10.0 Million Private Placement (Business Wire)
Oct-22-24 09:00AM	Coya Therapeutics Announces $10.0 Million Private Placement (Business Wire) +16.44%
Oct-08-24 09:15AM	Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 (Business Wire)
Sep-24-24 08:15AM	Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference (Business Wire)
Sep-16-24 08:15AM	Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease (Business Wire)
Sep-03-24 08:15AM	Coya Therapeutics to Present at Upcoming Healthcare Conferences (Business Wire)
Aug-19-24 09:00AM	Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 (Business Wire) +9.77%
Aug-12-24 08:00AM	Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results (Business Wire) -12.87%
Aug-02-24 08:15AM	Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Business Wire) -6.53%
Jul-31-24 08:15AM	Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (Business Wire)
Jun-20-24 08:15AM	Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic (Business Wire)
Jun-11-24 08:15AM	Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology (Business Wire) +12.68%
Jun-03-24 08:15AM	Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology (Business Wire)
May-28-24 08:15AM	Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index (Business Wire)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
11:43AM	EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases (Benzinga)
May-23-24 08:52AM	Coya Therapeutics concludes Phase II Alzheimers therapy trial (Clinical Trials Arena)
May-22-24 08:15AM	Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimers Disease (Business Wire)
May-20-24 09:10AM	Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation (MT Newswires)
08:15AM	Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF) (Business Wire)
May-10-24 03:54PM	Coya Therapeutics Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 04:10PM	Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results (Business Wire) +5.35%
Apr-26-24 08:15AM	Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium (Business Wire)
Apr-22-24 08:15AM	Coya Therapeutics to Participate in the Mizuho Neuroscience Summit (Business Wire)
Apr-18-24 08:15AM	Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit (Business Wire)
Apr-08-24 08:15AM	Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium (Business Wire)
Mar-21-24 05:31AM	Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates (GuruFocus.com)
Mar-19-24 09:53PM	COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023 (InvestorPlace)
08:15AM	Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results (Business Wire)
Mar-12-24 09:00AM	Coya Therapeutics to Participate in BTIG Fireside Discussion (Business Wire) -7.68%
08:00AM	Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference (Business Wire)
Mar-06-24 08:15AM	Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference (Business Wire)
Feb-29-24 08:15AM	Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference (Business Wire) -5.86%
Feb-22-24 08:15AM	Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference (Business Wire)
Feb-21-24 08:15AM	Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimers Disease and Coyas Pathway to a Pipeline in a Product (Business Wire) +7.94%
Feb-13-24 08:15AM	Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases (Business Wire)
Jan-29-24 08:15AM	Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference (Business Wire)
Jan-18-24 08:15AM	Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series (Business Wire)
Jan-16-24 08:15AM	Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinsons Disease in Addition to Amyotrophic Lateral Sclerosis (Business Wire) -10.27%
03:59AM	DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing (PR Newswire)
Jan-05-24 08:00AM	Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Dec-20-23 08:30AM	Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc. (Business Wire) -7.66%
Dec-14-23 03:54PM	David Einhorn's Greenlight Capital Boosts Coya Therapeutics Holding (GuruFocus.com)
03:54PM	David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfolio (GuruFocus.com)
Dec-13-23 08:00AM	Coya Therapeutics CEO Dr. Howard Bermans Letter to Stockholders (Business Wire)
Dec-12-23 08:00AM	Coya Therapeutics Announces Closing of $26.5 Million Private Placement (Business Wire)
Dec-06-23 07:05AM	Coya Therapeutics Announces $26.5 Million Private Placement (Business Wire)
07:00AM	Coya Therapeutics, Inc. and Dr. Reddys Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Nov-08-23 09:00AM	Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results (Business Wire)
Oct-27-23 09:00AM	Coya Announces Acceptance of Oral Presentation, Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimers Disease: A Phase 1 Feasibility Study, at the 18th International Conference on Alzheimers and Parkinsons Disease in Lisbon (Business Wire)
Oct-09-23 08:00AM	Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimers Disease (AD) (Business Wire)
Oct-05-23 09:00AM	Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire)
Oct-03-23 09:00AM	Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting (Business Wire) -5.38%
Sep-27-23 09:00AM	Coya Therapeutics to Present at the LD Micro Investor Conference (Business Wire)
Sep-22-23 09:00AM	Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU) (Business Wire)
Sep-07-23 09:15AM	Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases (Business Wire) +12.12%
Aug-31-23 08:00AM	Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing Therapies (Business Wire)
Aug-25-23 09:00AM	Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023 (Business Wire)
Aug-21-23 01:31PM	Headline (News Direct)
07:00AM	Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coyas Board of Directors (Business Wire)
Aug-08-23 07:00AM	Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results (Business Wire)
Aug-03-23 07:00AM	Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023 (Business Wire)
Jul-19-23 07:00AM	Coya Therapeutics ("Coya") Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (Business Wire)
Jul-17-23 12:21PM	Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation (Benzinga) +5.99%
07:00AM	Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimers Disease (Business Wire)
Jul-05-23 08:30AM	Coya Therapeutics ("Coya") Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner (Business Wire)
Jun-28-23 07:00AM	Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimers Disease (AD) at the 2023 Alzheimers Association International Conference (AAIC) (Business Wire)
Jun-20-23 07:00AM	Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD) (Business Wire)
Jun-14-23 07:00AM	Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs (Business Wire) -5.75%
Jun-12-23 07:00AM	Coya Therapeutics CEO Dr. Howard Bermans Letter to Stockholders (Business Wire)

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SNYDER DAVID S	Chief Financial Officer	Nov 14 '24	Buy	7.19	1,800	12,934	8,800	Nov 14 06:08 PM
Swaminathan Arun	Chief Executive Officer	Nov 13 '24	Buy	7.36	5,000	36,797	10,000	Nov 13 04:05 PM
Grossman Fred	Chief Medical Officer	Nov 11 '24	Buy	7.37	2,710	19,973	2,710	Nov 12 06:03 PM
Swaminathan Arun	Chief Executive Officer	Nov 11 '24	Buy	7.34	5,000	36,689	5,000	Nov 12 04:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COYA

Coya Therapeutics Inc

Upgrade your FINVIZ experience